{"prompt": "['48', 'MC1488 WEE1', 'MCCC', 'Relapse after CR or PR', 'At least one of the following:', 'Return to pretreatment bone marrow blast percentage', 'Decrement of >50% from maximum remission/response', 'levels in granulocytes or platelets', 'Reduction in hemoglobin concentration by 1.5g/Lor', 'transfusion dependence if previously had become', 'transfusion independent for > 8 weeks', 'Cytogenetic response', 'Complete:', 'Disappearance of the chromosomal abnormality without', 'appearance of new ones', 'Partial:', 'At least 50% reduction of the chromosomal abnormality', 'Disease progression', 'For patients with:', 'Less than 5% blasts: >50% increase in blasts to >5%', 'blasts', '5%-10% blasts: >50% increase in blasts to >10% blasts', '10%-20% blasts: >50% increase in blasts to >20% blasts', '20%-30% blasts: >50% increase in blasts to >30% blasts', 'Any of the following:', 'At least 50% decrement from maximum', 'remission/response levels in granulocytes or platelets', 'Reduction in hemoglobin concentration by >2 g/dL', 'Transfusion dependence if previously had become', 'transfusion independent for > 8 weeks', 'a', 'For a designated response (CR, PR), relevant response criteria must be noted on at least 2', 'successive determinations at least 1 week apart after an appropriate period following therapy', '(e.g., 1 month or longer).', 'c', 'In the absence of another explanation, such as acute infection, gastrointestinal bleeding,', 'hemolysis, etc.', 'Hematologic Improvement*', 'Response Criteria (responses must last at least 8 weeks)', 'Erythroid response', 'Hgb increase by >1.5 g/dL', '(pretreatment, Hgb < 11 g/dL)', 'Relevant reduction of units of red blood cell (RBC) transfusions', 'by an absolute number of at least 4 RBC transfusions/8 wk', 'compared with the pretreatment transfusion number in the', 'previous 8 wk. Only RBC transfusions given for an Hgb of 9.0', 'g/dL pretreatment will count in the RBC transfusion response', 'evaluation.', 'Platelet response', 'Absolute increase of > 30 X 109/L for patients starting with >20 X', '(pretreatment, < 100 X 10%/L)', '109/L', 'Increase from < 20 x 109/L to >20 X 109/L and by at least 100%', 'Neutrophil response', 'At least 100% increase and an absolute increase >0.5 x 109/L.', '(pretreatment, < 1.0 X 109/L)', 'Progression or relapse after HI', 'At least 1 of the following:', 'At least 50% decrement from maximum response levels', 'in granulocytes or platelets', 'Reduction in Hgb by 1.5g/dL', 'Transfusion dependence']['49', 'MC1488 WEE1', 'MCCC', '*', 'Pretreatment count averages of at least 2 measurements (not influenced by transfusions) >1', 'week apart (modification)', 'a', 'For a designated response (CR, PR, HI), relevant response criteria must be noted on at least 2', 'successive determinations at least 1 week apart after an appropriate period following therapy', '(e.g., 1 month or longer).', 'b In the absence of another explanation, such as acute infection, gastrointestinal bleeding,', 'hemolysis, etc.', '12.0', 'Descriptive Factors', '12.1', 'Transfusion Dependent: Yes vs No', '12.2', 'MDS subcategory: MDS VS MDS/MPN overlap VS CMML', '12.3', 'Previous cytotoxic chemotherapy: yes VS no', '12.4', 'AML subcategory: without prior HMA VS prior HMA', '12.5', 'HMA failure: refractory VS relapsed VS progressed on HMA', '12.6', 'AML: De novo VS secondary AML', '12.7', 'AML: newly diagnosed vs relapsed/refractory', '13.0', 'Treatment/Follow-up Decision at Evaluation of Patient', '13.1', 'Patients who have not developed PD will continue treatment per protocol.', '13.2', 'Patients who develop PD while receiving therapy will go to the event monitoring phase.', '13.3', 'Patients who go off protocol treatment for reasons other than PD will go to the event', 'monitoring phase per Section 18.0.', '13.4', 'If a patient in the initial safety portion fails to complete 28 days of treatment for reasons', 'other than dose-limiting toxicity defined adverse events, the patient will be regarded as', 'uninformative in regard and an additional patient will be treated; however, all toxicity', 'information will be utilized in the analysis.', '13.5', 'A patient is deemed ineligible if after registration, it is determined that at the time of', 'registration, the patient did not satisfy each and every eligibility criteria for study entry.', 'The patient will go directly to the event monitoring phase of the study (or off study, if', 'applicable).', 'If the patient received treatment, all data up until the point of confirmation of', 'ineligibility must be submitted. Event monitoring will be required per Section 18.0', 'of the protocol.', 'If the patient never received treatment, on-study material and the End of Active', 'Treatment/Cancel Notification Form must be submitted. No further data submission']\n\n###\n\n", "completion": "END"}